INFED Drug Patent Profile
✉ Email this page to a colleague
When do Infed patents expire, and what generic alternatives are available?
Infed is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in INFED is iron dextran. There are eighty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the iron dextran profile page.
US Patents and Regulatory Information for INFED
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | INFED | iron dextran | INJECTABLE;INJECTION | 017441-001 | Approved Prior to Jan 1, 1982 | BP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
